Chronic granulomatous disease (CGD) is a genetic disorder in which white blood cells called phagocytes are unable to kill certain types of bacteria and fungi. People with CGD are highly susceptible to infections, such as Staphylococcus aureus, Serratia marcescens, Burkholderia cepacia, Nocardia species, and Aspergillus species. NIAID aims to improve diagnosis, explore new treatments and preventions, and facilitate genetic counseling for this primary immune deficiency disease.
Current Clinical Research Studies Seeking Volunteers
The following are selected NIAID-supported clinical research activities that are seeking participation by CGD patients. The links lead to full study descriptions, eligibility criteria and contact information.
This study evaluates the feasibility, safety, and to a lesser extent, efficacy of radiofrequency ablation to treat liver abscesses in subjects with previously diagnosed CGD.
This study will determine the long-term medical condition and daily functioning of participants with CGD after a transplant and if possible, compare these results to participants who do not undergo a transplant.
This protocol is designed to study the techniques needed to develop gene therapy or other treatments for certain inherited immune system diseases.
The objective of this study is to learn more about when and why inflammatory bowel syndrome may develop in some people with primary immunodeficiency diseases.
Study of Gene Therapy Using a Lentiviral Vector to Treat X-linked Chronic Granulomatous Disease (NCT02234934)
This study assesses the safety, feasibility and efficacy of cellular gene therapy in patients ages 23 months and older with chronic granulomatous disease using bone marrow transplant.
The objective of this study is to collect data on people with primary immune deficiency disorders.
This study will evaluate patients with abnormal immune function that results in recurrent or unusual infections or chronic inflammation.